The Governors Of The University Of Calgary

The Governors Of The University Of Calgary (doing business as University Of Calgary), headquartered in Calgary, Alberta, Canada, is a Canadian international educational and research institution that receives federal research funding as a prime grant recipient and as a subcontractor on federally funded research projects, with no federal prime contracting role. The institution operates across multiple research disciplines anchored in biomedical science, life sciences, and computational biology, competing in full-and-open research grant programs rather than set-asides.

University of Calgary has received prime federal grants totaling $869,000 in combined potential value across 157 awards over the past several years, with recent grant activity spanning the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420), the National Institutes of Health across multiple institutes (NIAID, NCI, NIAM, NIMH), the U.S. Fish and Wildlife Service's Fish and Wildlife Coordination and Assistance Program (CFDA 15.664), and the National Institute of Neurological Disorders and Stroke. Representative prime grant work includes a $345,837 definitive contract awarded by the Food and Drug Administration on September 30, 2026 for regulatory science tool development supporting transcranial ultrasound modeling, running through September 2027 (EO 14398 execution); a $892,929 project grant from the Defense Health Agency for early detection blood test development for universal breast cancer screening, with performance through June 2027; a $186,865 cooperative agreement from U.S. Fish and Wildlife Service Region 7 (CFDA 15.664) awarded June 1, 2025 to develop novel trace-element methods for differentiating coastal Western Alaskan chum salmon stocks, completing May 31, 2027; and multiple Defense Health Agency project grants spanning multiple sclerosis research (proteopathy mechanisms, angiogenesis-hypoxia biomarkers, remyelination inhibitors, endogenous repair approaches) and spinal cord injury intervention development (baroprosthesis device design).

Prime grants dominate the portfolio at 43% of all awards (67 of 157), with Defense Health Agency (22 awards across military medical research), NIH National Institute of Allergy and Infectious Diseases (20 awards), NIH broadly (13 awards), NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (10 awards), and NIH National Institute of Mental Health (10 awards) accounting for 48% of award volume. Potential-value concentration follows a different pattern, with NIH National Cancer Institute (3 awards, $131 thousand combined potential value), CDC Office of Acquisition Services (2 awards, $130 thousand), and Navy Naval Air Warfare Center (3 awards, $85 thousand) leading the top-five ranking by dollars.

University of Calgary operates predominantly as a subgrantee on NIH-funded research managed by prime recipients including the University of Pittsburgh, Yale University, Johns Hopkins University, University of Florida, University of Washington, and Washington University, performing specialized research tasks including morphometric and computational analysis of biological datasets (microCT scanning, finite element analysis, genetic sequencing, metabolic assays, clinical data management) across clinical trials and basic research programs in orthopedic surgery (ACL reconstruction, knee ligament injuries), neurology (multiple sclerosis disease mechanisms, Alzheimer disease), infectious disease (Lyme disease, cystic fibrosis antibiotic resistance, gonococcal drug resistance), and primatology (microbiome aging, behavioral ecology). The institution also subcontracts to Northwestern University on multiple cycles of structural biology of infectious diseases research, providing scientific support across fiscal years 2024–2026.

The source identifies 90 sub-awards (57% of the portfolio) spanning both contract and grant sub-awards, with the SCI dataset showing 8 service-contract records, all in the subcontractor role, across fiscal years 2022–2025 with no prime service-contract reporting. SCI-reported federal services activity shows 2.1 FTEs in FY2022, 5.5 FTEs in FY2024, and 4.6 FTEs in FY2025, reflecting sporadic engagement on named subcontracts above the $150,000 reporting threshold; the SCI figures are a partial view of the institution's federal services footprint and exclude grants, goods, and non-federal revenue.

Recent activity has grown unevenly—from 14 awards in 2022 to a peak of 28 in 2024, then 23 in 2025 and 9 through September 2026. Four awards (combined potential value $346,000) are scheduled for completion within the next twenty-four months, creating limited recompete exposure. University of Calgary's research portfolio is concentrated in biotechnology R&D (6 awards), higher education institution research (6 awards), and health R&D services (3 awards in PSC coding), with recurring engagement from health, life sciences, and defense research customers across civilian and military medical research funding streams.